Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $76.4 million.

  • Nurix Therapeutics' Shares Outstanding (Weighted Average) rose 18.69% to $76.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $76.4 million, marking a year-over-year increase of 18.69%. This contributed to the annual value of $70.8 million for FY2024, which is 46.04% up from last year.
  • Nurix Therapeutics' Shares Outstanding (Weighted Average) amounted to $76.4 million in Q3 2025, which was up 0.28% from $76.2 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) peaked at $76.4 million during Q3 2025, and registered a low of $38.9 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $64.4 million (2024), whereas its average is $60.8 million.
  • Data for Nurix Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 55.21% (in 2025) over the last 5 years.
  • Over the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $44.6 million in 2021, then climbed by 5.96% to $47.3 million in 2022, then rose by 2.60% to $48.5 million in 2023, then soared by 46.04% to $70.8 million in 2024, then climbed by 18.69% to $76.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $76.4 million in Q3 2025, compared to $76.2 million in Q2 2025 and $75.9 million in Q1 2025.